Literature DB >> 10952646

The relationship of genotype to cognitive outcome in galactosaemia.

J P Shield1, E J Wadsworth, A MacDonald, A Stephenson, L Tyfield, J B Holton, N Marlow.   

Abstract

AIMS: To evaluate the cognitive outcome of a cohort of children with galactosaemia in relation to genotype.
METHODS: The cohort was drawn from children notified to the British Paediatric Surveillance Unit galactosaemia study which ran from 1988 to 1990. Cognitive outcome was assessed using the Wechsler Intelligence Scale for Children or the Wechsler Preschool and Primary Scale of Intelligence. Parents completed a questionnaire detailing educational status, and the attending paediatrician returned a questionnaire regarding age at diagnosis and biochemical outcome over the previous two years.
RESULTS: A total of 45 children were genotyped: 30 were homoallelic for the Q188R mutation, the remainder being heteroallelic for Q188R with K285N (n = 4), L195P (n = 4), or other mutations (n = 7). Psychometric evaluation was available in 34 cases: mean full scale IQ was 79, verbal quotient 79, and performance quotient 82. Genotype was not related to galactose-1-phosphate (Gal-1-P) concentrations. However, children homoallelic for the Q188R mutation had significantly lower IQ scores than those who were heteroallelic (73. 6 v 94.8). This difference was independent of social and demographic influences and Gal-1-P concentrations over the previous two years.
CONCLUSIONS: In children with galactosaemia, cognitive outcome appears to relate to genotype rather than metabolic control, as reflected by Gal-1-P concentrations. The value of measuring Gal-1-P concentrations routinely once successfully established on a galactosaemia diet is questionable as concentrations do not appear to affect outcome. In the UK population, homozygosity for the Q188R mutation is invariably associated with a poor outcome, and there is evidence that variability in neurocognitive outcome is at least part dependent on allelic heterogeneity.

Entities:  

Mesh:

Year:  2000        PMID: 10952646      PMCID: PMC1718484          DOI: 10.1136/adc.83.3.248

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  13 in total

1.  Long-term prognosis in galactosaemia: results of a survey of 350 cases.

Authors:  D D Waggoner; N R Buist; G N Donnell
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

2.  A mouse model of galactose-1-phosphate uridyl transferase deficiency.

Authors:  N D Leslie; K L Yager; P D McNamara; S Segal
Journal:  Biochem Mol Med       Date:  1996-10

3.  Galactosaemia: relationship of IQ to biochemical control and genotype.

Authors:  M A Cleary; L E Heptinstall; J E Wraith; J H Walter
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

4.  Galactosaemia: results of the British Paediatric Surveillance Unit Study, 1988-90.

Authors:  M M Honeyman; A Green; J B Holton; J V Leonard
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

Review 5.  Classical galactosemia and mutations at the galactose-1-phosphate uridyl transferase (GALT) gene.

Authors:  L Tyfield; J Reichardt; J Fridovich-Keil; D T Croke; L J Elsas; W Strobl; L Kozak; T Coskun; G Novelli; Y Okano; C Zekanowski; Y Shin; M D Boleda
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

6.  Correlation of cognitive, neurologic, and ovarian outcome with the Q188R mutation of the galactose-1-phosphate uridyltransferase gene.

Authors:  F R Kaufman; J K Reichardt; W G Ng; Y K Xu; F R Manis; C McBride-Chang; J A Wolff
Journal:  J Pediatr       Date:  1994-08       Impact factor: 4.406

7.  Molecular characterization of two galactosemia mutations: correlation of mutations with highly conserved domains in galactose-1-phosphate uridyl transferase.

Authors:  J K Reichardt; S Packman; S L Woo
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

8.  Long-term outcome in 134 patients with galactosaemia.

Authors:  S Schweitzer; Y Shin; C Jakobs; J Brodehl
Journal:  Eur J Pediatr       Date:  1993-01       Impact factor: 3.183

9.  Mutations in the galactose-1-phosphate uridyltransferase gene of two families with mild galactosaemia variants.

Authors:  M Sommer; B S Gathof; T Podskarbi; R Giugliani; B Kleinlein; Y S Shin
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

10.  Galactosemia: a strategy to identify new biochemical phenotypes and molecular genotypes.

Authors:  L J Elsas; S Langley; E Steele; J Evinger; J L Fridovich-Keil; A Brown; R Singh; P Fernhoff; L N Hjelm; P P Dembure
Journal:  Am J Hum Genet       Date:  1995-03       Impact factor: 11.025

View more
  21 in total

1.  Classical Galactosaemia in Ireland: incidence, complications and outcomes of treatment.

Authors:  K P Coss; P P Doran; C Owoeye; M B Codd; N Hamid; P D Mayne; E Crushell; I Knerr; A A Monavari; E P Treacy
Journal:  J Inherit Metab Dis       Date:  2012-07-03       Impact factor: 4.982

2.  Arginine Functionally Improves Clinically Relevant Human Galactose-1-Phosphate Uridylyltransferase (GALT) Variants Expressed in a Prokaryotic Model.

Authors:  Ana I Coelho; Matilde Trabuco; Maria João Silva; Isabel Tavares de Almeida; Paula Leandro; Isabel Rivera; João B Vicente
Journal:  JIMD Rep       Date:  2015-03-27

3.  Living situation, occupation and health-related quality of life in adult patients with classic galactosemia.

Authors:  Björn Hoffmann; Nico Dragano; Susanne Schweitzer-Krantz
Journal:  J Inherit Metab Dis       Date:  2012-03-24       Impact factor: 4.982

4.  Cross-sectional analysis of speech and cognitive performance in 32 patients with classic galactosemia.

Authors:  Björn Hoffmann; Udo Wendel; Susanne Schweitzer-Krantz
Journal:  J Inherit Metab Dis       Date:  2011-02-24       Impact factor: 4.982

Review 5.  Classical galactosaemia revisited.

Authors:  Annet M Bosch
Journal:  J Inherit Metab Dis       Date:  2006-07-11       Impact factor: 4.982

6.  Partial effect of bromocriptine on lactose and galactose synthesis in a pregnant woman heterozygous for galactosaemia.

Authors:  M Odièvre; M Brivet; M F Rivière; P Labrune
Journal:  J Inherit Metab Dis       Date:  2001-08       Impact factor: 4.982

7.  Diversity of approaches to classic galactosemia around the world: a comparison of diagnosis, intervention, and outcomes.

Authors:  Patricia P Jumbo-Lucioni; Kathryn Garber; John Kiel; Ivo Baric; Gerard T Berry; Annet Bosch; Alberto Burlina; Ana Chiesa; Maria Luz Couce Pico; Sylvia C Estrada; Howard Henderson; Nancy Leslie; Nicola Longo; Andrew A M Morris; Carlett Ramirez-Farias; Susanne Schweitzer-Krantz; Susanne Scheweitzer-Krantz; Catherine Lynn T Silao; Marcela Vela-Amieva; Susan Waisbren; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2012-03-27       Impact factor: 4.982

8.  A frequent splicing mutation and novel missense mutations color the updated mutational spectrum of classic galactosemia in Portugal.

Authors:  Ana I Coelho; Ruben Ramos; Ana Gaspar; Cláudia Costa; Anabela Oliveira; Luísa Diogo; Paula Garcia; Sandra Paiva; Esmeralda Martins; Elisa Leão Teles; Esmeralda Rodrigues; M Teresa Cardoso; Elena Ferreira; Sílvia Sequeira; Margarida Leite; Maria João Silva; Isabel Tavares de Almeida; João B Vicente; Isabel Rivera
Journal:  J Inherit Metab Dis       Date:  2013-06-08       Impact factor: 4.982

9.  Cryptic residual GALT activity is a potential modifier of scholastic outcome in school age children with classic galactosemia.

Authors:  Emily L Ryan; Mary Ellen Lynch; Elles Taddeo; Tyler J Gleason; Michael P Epstein; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2013-01-15       Impact factor: 4.982

10.  Classical Galactosaemia and CDG, the N-Glycosylation Interface. A Review.

Authors:  Ashwini Maratha; Hugh-Owen Colhoun; Ina Knerr; Karen P Coss; Peter Doran; Eileen P Treacy
Journal:  JIMD Rep       Date:  2016-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.